Sandu Pharmaceuticals Holds 41st AGM, Presents FY26 Report

Sandu Pharmaceuticals Limited has released its 41st Annual Report for the financial year 2025-26, coinciding with the notice for its 41st Annual General Meeting (AGM) scheduled for September 11, 2026. The AGM will be conducted via Video Conferencing (VC/OAVM). The report highlights a revenue of ₹6,993.45 lakhs and a notable 23.187% increase in net profit, attributed to operational efficiencies and cost management. The company emphasizes its commitment to Ayurvedic traditions, innovation in product development, and sustainability initiatives, including eco-friendly practices and community welfare. Sandu Pharmaceuticals is investing in R&D, infrastructure modernization, and brand building to drive future growth and long-term stakeholder value.